Product and methods useful for modulating and evaluating immune responses

An isolated dendritic cell comprising a recombinant nucleic acid encoding an antigen, wherein the dendritic cell is selected from the group consisting of:

• e1) a dendritic cell characterized in that the dendritic cell comprises expression of HLA-DR, does not express CD3, CD56, CD19 and CD14, and comprises expression of one or more genes or gene products selected from the group consisting of AXL (AXL Receptor Tyrosine Kinase), SIGLEC6, SIGLEC1, PPP1R14A, CD22, CD5, and GPR146;
• e2) a dendritic cell which is HLA-DR positive, CD3 negative, CD56 negative, CD19 negative and CD14 negative, and positive for one or more genes or gene products selected from the group consisting of AXL, SIGLEC6, SIGLEC1, PPP1R14A, CD22, CD5, and GPR146;
• e3) a dendritic cell characterized in that the dendritic cell comprises expression of HLA-DR, does not express CD3, CD56, CD19 and CD14, and comprises a gene or gene product signature, the signature comprising one or more genes or gene products selected from AXL, PPP1R14A, SIGLEC6, CD22, DAB2, S100A10, FAM105A, MED12L, ALDH2, LTK, DPYSL2, LGMN, IRF4, SEPT6, PLAC8, CCND3, MYO1E, SLC41A2, SCN9A, SIGLEC1, CX3CR1, NDRG1, VASH1, CD5, BHLHE40, SNRNP25, USF2, SLC20A1, ATF5, FAM129A, KLF4, RUNX2, ARHGAP18, APEX1, ENTPD7, SLC35C2, CDH1, GPR146, BAIAP2, CDKN1A, UPK3A, GNAQ, THBD, TNFSF12, SOX4, CXCR2, HIP1, STX18, CTSW, ATP2B4, CD72, MGLL, SUSD1, RNF141, TNNI2, GGTA1P, C5ORF25, PTGDS, TSEN54, KLF12, MYH11, TXN, AK125727, CD300LB, SUCLA2, BIN1, MRPS6, ZNF789, RAD1, PIM2, PLA2G16, TBC1D9, ADAM33, ZEB1, CD300LG, SLC4A3, STAG3L4, MECR, COQ7, RBL1, CEP95, RNASEL, ACPP, SP4, or LAX1;
• the dendritic cell as defined in e1) comprises expression of two or more, three or more, four or more, five or more, six or more, or all genes or gene products selected from the group consisting of AXL, SIGLEC6, SIGLEC1, PPP1R14A, CD22, CD5, and GPR146;
• the dendritic cell as defined in e1) comprises expression of AXL and SIGLEC6;
• the dendritic cell as defined in e2) is positive for two or more, three or more, four or more, five or more, six or more, or all genes or gene products selected from the group consisting of AXL, SIGLEC6, SIGLEC1, PPP1 R14A, CD22, CD5, and GPR146;
• the dendritic cell as defined in e2) is AXL positive and SIGLEC6 positive;
• the dendritic cell as defined in any one of e1), e2), or e3) does not express CD141, or CD16, or CD141 and CD16;
• the dendritic cell as defined in any one of e1), e2), or e3) is CD141 negative, or CD16 negative, or CD141 negative and CD16 negative;
• the dendritic cell as defined in any one of e1), e2), or e3) comprises expression of CD123 and does not express CD11C;
• the dendritic cell as defined in any one of e1), e2), or e3) is CD123 positive and CD11C negative (CD123+CD11C−);
• the dendritic cell as defined in any one of e1), e2), or e3) comprises a gene or gene product signature, the signature comprising one or more genes or gene products selected from the group consisting of PROC, IRF8, FMNL3, APP, SERPINF1, C1ORF186, CYBASC3, PLAC8, NRP1, CCDC50, TSPAN13, UGCG, LILRA4, MZB1, PTPRS, AK128525, IGJ, and IL3RA;
• the dendritic cell as defined in any one of e1), e2), or e3) does not express ITGAX;
• the dendritic cell as defined in any one of e1), e2), or e3) does not express CD123 and comprises expression of CD11C;
• the dendritic cell as defined in any one of e1), e2), or e3) is CD123 negative and CD11C positive (CD123−CD11C+);
• the dendritic cell as defined in any one of e1), e2), or e3) comprises a gene or gene product signature, the signature comprising one or more genes or gene products selected from the group consisting of ITGAX, IFI30, LGALS2, FGR, LY86, GLIPR2, TIMP1, LST1, AGPAT9, IFITM3, DUSP23, ENTPD1, LOC645638, and IL1RN;
• or
• the dendritic cell as defined in any one of e1), e2), or e3) comprises expression of ITGAX.